Residual macrovascular risk in 2013: what have we learned?

Cardiovascular disease poses a major challenge for the 21st century, exacerbated by the pandemics of obesity, metabolic syndrome and type 2 diabetes. While best standards of care, including high-dose statins, can ameliorate the risk of vascular complications, patients remain at high risk of cardiova...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cardiovascular Diabetology 2014-01, Vol.13 (1), p.26-26, Article 26
Hauptverfasser:	Fruchart, Jean-Charles, Davignon, Jean, Hermans, Michel P, Al-Rubeaan, Khalid, Amarenco, Pierre, Assmann, Gerd, Barter, Philip, Betteridge, John, Bruckert, Eric, Cuevas, Ada, Farnier, Michel, Ferrannini, Ele, Fioretto, Paola, Genest, Jacques, Ginsberg, Henry N, Gotto, Jr, Antonio M, Hu, Dayi, Kadowaki, Takashi, Kodama, Tatsuhiko, Krempf, Michel, Matsuzawa, Yuji, Núñez-Cortés, Jesús Millán, Monfil, Carlos Calvo, Ogawa, Hisao, Plutzky, Jorge, Rader, Daniel J, Sadikot, Shaukat, Santos, Raul D, Shlyakhto, Evgeny, Sritara, Piyamitr, Sy, Rody, Tall, Alan, Tan, Chee Eng, Tokgözoğlu, Lale, Toth, Peter P, Valensi, Paul, Wanner, Christoph, Zambon, Alberto, Zhu, Junren, Zimmet, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Apolipoproteins Cardiovascular agents Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cardiovascular Diseases - therapy Care and treatment Cholesterol Colleges & universities Complications and side effects Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - therapy Dyslipidemias - diagnosis Dyslipidemias - epidemiology Dyslipidemias - therapy Evidence-based medicine Health aspects Hospitals Humans Learning Metabolic disorders Monoclonal antibodies Obesity Patient outcomes Pharmaceutical industry Review Risk Factors Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!